


CD39

Anti-CD39 Products
- Human Anti-CD39 Antibody, mRNA (TAB-123CL-mRNA)
-
- Species Reactivity: Human
- Mouse Anti-CD39 Recombinant Antibody (clone A1) (NEUT-350CQ)
-
- Species Reactivity: Human
- Type: Mouse IgG1
- Application: WB, Block, IF, FC
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: ADCC enhanced antibody
- Anti-Human CD39 Recombinant Antibody (TAB-123CL)
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Antibody
- Mouse Anti-CD39 Recombinant Antibody; Fab Fragment (TAB-159LC-F(E)) (TAB-159LC-F(E))
-
- Species Reactivity: Human
- Type: Mouse Fab
- Application: FC
- Mouse Anti-CD39 Recombinant Antibody; scFv Fragment (TAB-159LC-S(P)) (TAB-159LC-S(P))
-
- Species Reactivity: Human
- Type: Mouse scFv
- Application: FC
- Mouse Anti-CD39 Recombinant Antibody (TAB-159LC) (TAB-159LC)
-
- Species Reactivity: Human
- Type: Mouse IgG
- Application: FC, Inhib, FuncS
-
- Species Reactivity: Mouse
- Type: Rabbit IgG
- Application: ELISA
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: Mouse IgG1
- Application: WB
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: Mouse IgG1
- Application: IHC
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
At Creative Biolabs, we're passionately committed to offering high-end recombinant antibodies. Crafted with meticulous attention to stringent standards and bolstered by exceptional technical support, our products are designed to propel CD39 research forward. Our unwavering pursuit of excellence guarantees researchers reliable resources for comprehensive biological and clinical studies, aiming to drive breakthroughs in exploring CD39's disease-related roles and therapeutic prospects.
CD39: A Significant Target in Cancer and autoimmune diseases
CD39, a cell surface enzyme, plays a pivotal part in regulating immune responses and metabolism, mainly by degrading extracellular nucleotides, which in turn impacts the immune microenvironment. This enzyme has drawn significant attention due to its involvement in various diseases. For example, in cancer, the overexpression of CD39 on tumor and immune cells within the tumor microenvironment can inhibit anti-tumor immunity and exploring CD39's role here may lead to the development of new therapies that reverse immune suppression and improve the effectiveness of cancer immunotherapies. Additionally, in autoimmune diseases like rheumatoid arthritis and multiple sclerosis, the dysregulation of CD39 can cause inflammation, and researching CD39 in these diseases might identify novel therapeutic targets for modulating immune responses and reducing disease symptoms. In short, studying CD39 holds great potential for enhancing the diagnosis and treatment of diseases characterized by immune dysregulation.
Alternative Names
ENTPD1; SPG64; ATP-DPH; ATPDase; NTPDase-1
Background
The antibodies against human CD39 can be used for the treatment or prevention of cancers and infectious diseases.
Anti-CD39 rAb Products
We are wholeheartedly dedicated to presenting top-notch antibody products. Our experienced scientists use advanced tech and strict quality control. They strive to meet the diverse research needs of those studying CD39's role in immunity, metabolism, and diseases. Whether for basic or clinical research, our products are reliable tools every step of the way.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-123CL | Anti-Human CD39 Recombinant Antibody | Human | Human | ELISA |
TAB-159LC | Mouse Anti-CD39 Recombinant Antibody | Human | Mouse | FC; Inhib; FuncS |
HPAB-0177-CN | Mouse Anti-ENTPD1 Recombinant Antibody | Human | Mouse | ELISA; FC |
HPAB-M0475-YC | Mouse Anti-ENTPD1 Recombinant Antibody (clone mAb1) | Human | Mouse | Inhib |
HPAB-M0477-YC | Mouse Anti-ENTPD1 Recombinant Antibody (clone mAb3) | Human | Mouse | ELISA |
Customer Reviews

Anti-Human CD39 Recombinant Antibody (Cat#: TAB-123CL)

Mouse Anti-CD39 Recombinant Antibody (Cat#: TAB-159LC)
rAb Production
Boasting years of in-depth experience in vector design, cell transfection, and large-scale antibody production, we provide an all-inclusive service. Starting from gene synthesis, we guide customers through every step until the final antibody production. Our meticulous quality control is implemented at each stage, guaranteeing that clients obtain antibodies with the highest quality and remarkable stability.
Featured Anti-CD39 Recombinant Antibody Production Platforms
Fig.1 Milligram-scale recombinant antibody production.
Fig.2 Gram-scale recombinant antibody production.
rAb Modalities
Creative Biolabs extends a warm welcome to researchers by presenting an extensive array of high-caliber recombinant antibodies. These come in multiple formats. For instance, full length antibodies offer complete functionality, while scFv provides high flexibility. Our standardized production procedures, paired with premier services, ensure that researchers' multifaceted needs are met. From initial consultation to final product delivery, we're with you, providing state-of-the-art antibody solutions.
Fig.3 Full Length Anti-CD39 Recombinant Antibody Production and Modalities.
Drug Information Targeting CD39
Table 1. Therapeutic approaches targeting CD39 in clinical development.
Research phase | Company | Classification | Indications | Details |
Phase II | Novartis | Biologics | Acute kidney injury | This is a recombinant human CD39 enzyme developed at Novartis. The company is conducting phase II clinical trials for the intravenous treatment of patients with sepsis-associated acute kidney injury and patients at risk for acute kidney injury following cardiac surgery. |
Phase II | AbbVie | Biologics | Cancer | It is a monoclonal antibody that targets ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1, CD39) in phase II clinical development at Trishula Therapeutics, a spin-off of Tizona Therapeutics, as first-line treatment of metastatic pancreatic ductal adenocarcinoma, in combination with chemotherapy, with or without budigalimab. |
Phase II | Surface Oncology | Biologics | Cancer | It is a surface Oncology's human monoclonal antibody targeting CD39, was evaluated in phase II clinical trials for metastatic castration-resistant prostate cancer. |
Phase II |
AstraZeneca Innate Pharma |
Biologics | Cancer | It is a humanized monoclonal antibody targeting CD39, is in phase II clinical development at Innate Pharma for the treatment of non-small cell lung cancer (NSCLC), and in early clinical development for the treatment for patients with advanced solid tumors, both as monotherapy and in combination with oleclumab and/or durvalumab. |
Phase I | Arcus Biosciences | Biologics | Cancer | It is in early clinical development at Arcus Biosciences as an intravenous anticancer immunotherapeutic. |
Phase I | Beijing Eirene Biotech | Biologics | Cancer | It is a fully human anti- CD39 monoclonal antibody jointly developed by Junshi Biosciences and Beijing Eirene Biotech in early clinical evaluation as monotherapy in patients with advanced malignant solid tumors or lymphomas. |
Phase I | Elpiscience BioPharma | Biologics | Cancer | This is a first-in-class anti-CD39xTGF-beta bispecific antibody in phase I development at Elpiscience BioPharma for the treatment of patients with advanced solid tumors. |
Phase I | Elpiscience BioPharma | Biologics | Cancer | This is a humanized monoclonal antibody targeting CD39 in early clinical development at Elpiscience Biopharmaceuticals for the treatment of locally advanced or metastatic solid tumors. |
Should you need more details about the target CD39, don't hesitate to reach out at your leisure. Our team, composed of experts well-versed in CD39-related research, is fully prepared to handle all your inquiries. Whether it's clarifying research concepts or offering product-related advice, we're eager to answer your questions and back your research efforts.